{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T12:26:25Z","timestamp":1648556785409},"reference-count":27,"publisher":"Akademiai Kiado Zrt.","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orvosi Hetilap"],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:p>Introduction: The authors present and analyze the outcome of DIABOBHU observational study. The work was carried out in Hungarian type 2 diabetic patients whose treatment was insufficient with oral antidiabetic agents. Aim: The safety and efficacy of glargine insulin added to oral antidiabetic therapy treatment was evaluated. Method: Between 2008 and 2011 3955 patients were enrolled. After proper education, patients titrated the insulin dosage under self-monitoring with the help of their attending physicians. During the 26-week study period 3 visits were included. The primary endpoint was the change of HbA<jats:sub>1c<\/jats:sub>. The secondary endpoints were fasting glucose levels, dose of insulin, body weight and body mass index, satisfaction of the patients with the treatment and the incidence of hypoglycemic events. Results: During the study mean HbA<jats:sub>1c<\/jats:sub>decreased from 8.94% to 7.31%. Most patients achieved the glycemic goals with very low frequency of hypoglycemia. The patients did not gain weight and were satisfied with their treatment. Conclusions: The authors emphasize that this treatment based on an analogue basal insulin should be considered as an effective and safe therapy. Orv. Hetil., 2014, 155(23), 903\u2013910.<\/jats:p>","DOI":"10.1556\/oh.2014.29927","type":"journal-article","created":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T01:00:55Z","timestamp":1401584455000},"page":"903-910","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the DIABOBHU Observational Study"],"prefix":"10.1556","volume":"155","author":[{"given":"Zsolt","family":"Ga\u00e1l","sequence":"first","affiliation":[{"name":"Szabolcs-Szatm\u00e1r-Bereg Megyei K\u00f3rh\u00e1zak \u00e9s Egyetemi Oktat\u00f3k\u00f3rh\u00e1z, J\u00f3sa Andr\u00e1s Oktat\u00f3k\u00f3rh\u00e1z IV. Belgy\u00f3gy\u00e1szat Ny\u00edregyh\u00e1za Szent Istv\u00e1n u. 68. 4400"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsuzsanna","family":"Papp","sequence":"additional","affiliation":[{"name":"Szabolcs-Szatm\u00e1r-Bereg Megyei K\u00f3rh\u00e1zak \u00e9s Egyetemi Oktat\u00f3k\u00f3rh\u00e1z, J\u00f3sa Andr\u00e1s Oktat\u00f3k\u00f3rh\u00e1z IV. Belgy\u00f3gy\u00e1szat Ny\u00edregyh\u00e1za Szent Istv\u00e1n u. 68. 4400"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barnab\u00e1s","family":"Bak\u00f3","sequence":"additional","affiliation":[{"name":"Borsod-Aba\u00faj-Zempl\u00e9n Megyei K\u00f3rh\u00e1z \u00e9s Egyetemi Oktat\u00f3k\u00f3rh\u00e1z II. Belgy\u00f3gy\u00e1szat Miskolc"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, <i>352<\/i>(9131), 837\u2013853.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2","doi-asserted-by":"crossref","unstructured":"<i>Turner, R. C., Cull, C. A., Frighi, V., et al., for the UK hospective Diabetes Study (UKPDS) Group:<\/i> Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA, 1999<i>, 281<\/i>(21), 2005\u20132012.","DOI":"10.1001\/jama.281.21.2005"},{"key":"3","doi-asserted-by":"crossref","unstructured":"<i>Korytkowski, M.:<\/i> When oral agents fail: practical barriers to starting insulin. Int. J. Obes. Relat. Metab. Disord., 2002, <i>26<\/i>(Suppl. 3), S18\u2013S24.","DOI":"10.1038\/sj.ijo.0802173"},{"key":"4","doi-asserted-by":"crossref","unstructured":"<i>Cryer, P., Childs, B. P.:<\/i> Negotiating the barrier of hypoglycemia in diabetes. Diabetes Spectrum, 2002, <i>15<\/i>(1), 20\u201327.","DOI":"10.2337\/diaspect.15.1.20"},{"key":"5","doi-asserted-by":"crossref","unstructured":"<i>Cryer, P. E.:<\/i> Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab. Res. Rev., 1999, <i>15<\/i>(1), 42\u201346.","DOI":"10.1002\/(SICI)1520-7560(199901\/02)15:1<42::AID-DMRR1>3.0.CO;2-B"},{"key":"6","unstructured":"AACE: The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management \u2013 2000 update. Endocr. Pract., 2000, <i>6<\/i>(1), 43\u201384."},{"key":"7","doi-asserted-by":"crossref","unstructured":"European Diabetes Policy Group 1999: A desktop guide to type 2 diabetes mellitus. Diabet. Med., 1999, <i>16<\/i>(9), 716\u2013730.","DOI":"10.1046\/j.1464-5491.1999.00166.x"},{"key":"8","unstructured":"NICE: Clinical guidelines for type 2 diabetes: management of blood glucose [article online], 2002. London, NICE. <a href=\"http:\/\/www.nice.org.uk\">http:\/\/www.nice.org.uk<\/a>"},{"key":"9","doi-asserted-by":"crossref","unstructured":"<i>Barnett, A. H.:<\/i> A review of basal insulins. Diabet. Med., 2003, <i>20<\/i>(11), 873\u2013885.","DOI":"10.1046\/j.1464-5491.2003.00996.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"<i>Bolli, G. B.:<\/i> The pharmacokinetic basis of insulin therapy in diabetes mellitus. Diabetes Res. Clin. Pract., 1989, <i>6<\/i>(4), S3\u2013S16.","DOI":"10.1016\/0168-8227(89)90073-9"},{"key":"11","doi-asserted-by":"crossref","unstructured":"<i>Binder, C., Lauritzen, T., Faber, O., et al.:<\/i> Insulin pharmacokinetics. Diabetes Care, 1984, <i>7<\/i>(2), 188\u2013199.","DOI":"10.2337\/diacare.7.2.188"},{"key":"12","doi-asserted-by":"crossref","unstructured":"<i>Yki-J\u00e4rvinen, H.:<\/i> Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue. Eur. J. Clin. Invest., 2004, <i>34<\/i>(6), 410\u2013416.","DOI":"10.1111\/j.1365-2362.2004.01356.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"<i>Ratner, R.:<\/i> Insulin glargine versus NPH insulin in patients with type 1 diabetes. Drugs Today (Barc.), 2003<i>, 39<\/i>(11), 867\u2013876.","DOI":"10.1358\/dot.2003.39.11.799464"},{"key":"14","doi-asserted-by":"crossref","unstructured":"<i>Hermansen, K., Fontaine, P., Kukolja, K., et al.:<\/i> Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia, 2004<i>, 47<\/i>(4), 622\u2013629.","DOI":"10.1007\/s00125-004-1365-z"},{"key":"15","doi-asserted-by":"crossref","unstructured":"<i>Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., et al.:<\/i> Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2012, <i>55<\/i>(6), 1577\u20131596.","DOI":"10.1007\/s00125-012-2534-0"},{"key":"16","unstructured":"<i>Jermendy, Gy. (ed.):<\/i> Diagnosis of diabetes mellitus, treatment and care of diabetic petients. Guideleine of the Hungarian Diabetes Society 2011. [A diabetes mellitus k\u00f3rism\u00e9z\u00e9se, a cukorbetegek kezel\u00e9se \u00e9s gondoz\u00e1sa feln\u0151ttkorban. Magyar Diabetes T\u00e1rsas\u00e1g 2011. \u00e9vi szakmai ir\u00e1nyelve.] Diabetologia Hungarica, 2011, <i>19<\/i>(Suppl. 1), 5\u201372. [Hungarian]"},{"key":"17","doi-asserted-by":"crossref","unstructured":"<i>Chapman, T. M., Noble, S., Goa, K. L.:<\/i> Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs, 2002, <i>62<\/i>(13), 1945\u20131981.","DOI":"10.2165\/00003495-200262130-00014"},{"key":"18","doi-asserted-by":"crossref","unstructured":"<i>Lepore, M., Pampanelli, S., Fanelli, C., et al.:<\/i> Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes, 2000, <i>49<\/i>(12), 2142\u20132148.","DOI":"10.2337\/diabetes.49.12.2142"},{"key":"19","doi-asserted-by":"crossref","unstructured":"<i>Davies, M., Storms, F., Shutler, S.:<\/i> Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using glargine insulin. Diabetes Care, 2005, <i>28<\/i>(6), 1282\u20131288.","DOI":"10.2337\/diacare.28.6.1282"},{"key":"20","doi-asserted-by":"crossref","unstructured":"<i>Bethel, M. A., Feinglos, M. N.:<\/i> Basal inzulin therapy in type 2 diabetes. J. Am. Board Fam. Pract., 2005, <i>18<\/i>(3), 199\u2013204.","DOI":"10.3122\/jabfm.18.3.199"},{"key":"21","doi-asserted-by":"crossref","unstructured":"<i>Riddle, M. C., Rosenstock, J., Gerich, J., et al.:<\/i> The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 2003, <i>26<\/i>(11), 3080\u20133086.","DOI":"10.2337\/diacare.26.11.3080"},{"key":"22","doi-asserted-by":"crossref","unstructured":"<i>Yki-J\u00e4rvinen, H., Dressler, A., Ziemen, M., et al., HOE 901\/3002 Study Group:<\/i> Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime glargine insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care, 2000, <i>23<\/i>(8), 1130\u20131136.","DOI":"10.2337\/diacare.23.8.1130"},{"key":"23","doi-asserted-by":"crossref","unstructured":"<i>Wang, F., Carabino, J. M., Vergara, C. M.:<\/i> Insulin glargine: a systematic review of a long-acting insulin analogue. Clin. Ther., 2003, <i>25<\/i>(6), 1541\u20131577.","DOI":"10.1016\/S0149-2918(03)80156-X"},{"key":"24","doi-asserted-by":"crossref","unstructured":"<i>Dunn, C. J., Plosker, G. L., Keating, G. M., et al.:<\/i> Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs, 2003, <i>63<\/i>(16), 1743\u20131778.","DOI":"10.2165\/00003495-200363160-00007"},{"key":"25","doi-asserted-by":"crossref","unstructured":"<i>Kapitza, C., Forst, T., Coester, H. V., et al.:<\/i> Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes. Metab., 2013, <i>15<\/i>(7), 642\u2013649.","DOI":"10.1111\/dom.12076"},{"key":"26","doi-asserted-by":"crossref","unstructured":"<i>Gerstein, H. C., Bosch, J., Dagenais, G. R., et al.:<\/i> Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med., 2012, <i>367<\/i>(4), 319\u2013328.","DOI":"10.1056\/NEJMoa1203858"},{"key":"27","doi-asserted-by":"crossref","unstructured":"<i>Hanefeld, M., Bramlage, P.:<\/i> Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial. Curr. Diab. Rep., 2013, <i>13<\/i>(3), 342\u2013349.","DOI":"10.1007\/s11892-013-0366-z"}],"container-title":["Orvosi Hetilap"],"original-title":[],"language":"hu","link":[{"URL":"https:\/\/www.akademiai.com\/doi\/pdf\/10.1556\/OH.2014.29927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T09:55:43Z","timestamp":1590141343000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/doi\/10.1556\/oh.2014.29927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":27,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1556\/OH.2014.29927"],"URL":"https:\/\/doi.org\/10.1556\/oh.2014.29927","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}